Use the hyperlinks, where available to access additional clinical trial information.
A Phase II, Signal-Seeking Trial of the Clinical Benefit Rate Associated with Pamiparib in Subjects with Germline or Somatic BRCA1/2 High Grade Serous Ovarian Cancer or carcinosarcoma who have progressed on P-gp substrate chemotherapy or PARP inhibitors with the Presence of an ABCB1 Fusion and the Absence of a BRCA1/2 Reversion
Australia New Zealand Gynaecological Oncology Group (ANZGOG)
This phase II signal seeking trial is evaluating the clinical benefit of using a PARP inhibitor therapy (Pamiparib)for the treatment of patients with recurrent Germline or Somatic BRCA1/2 High Grade Serous Ovarian Cancer or carcinosarcoma, whose cancer progressed on chemotherapy or PARP inhibitors. Patients eligible for this trial will receive two doses of Pamiparib each day over a 28-day cycle. Participating patients can be treated continuously for up to 5 years.